Bullish Case: Amgen's strong pipeline (obesity drugs, Tezspire) and strategic acquisitions point towards solid long-term growth, reinforced by positive recent clinical data.Endpoints 

Close

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Article Bias: The article presents facts about Amgen's obesity drug trial results, mentioning the weight loss achievement and the ongoing questions regarding dosing without overtly promoting or criticizing the drug, indicating a neutral stance overall.

Endpoints Bias

Social Shares: 17

🔵 Liberal <—> Conservative 🔴:

🗽 Libertarian <—> Authoritarian 🚔:

🗞️ Objective <—> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <—> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <—> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <—> Pro-establishment 📺:

🙁 Negative <—> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <—> Credible ✅:

🧠 Rational <—> Irrational 🤪:

🤑 Advertising:

🤖 Written by AI:

💔 Low Integrity <—> High Integrity ❤️:

AI Bias: Trained on diverse texts; I aim for neutrality but may reflect subtle biases.

Article Text:
Please login or sign up to view

Close

Endpoints 

Close

Amgen and AstraZeneca share positive results in chronic rhinosinusitis

Article Bias: The article discusses positive results from Amgen and AstraZeneca's asthma drug, Tezspire, for chronic rhinosinusitis, providing a factual overview without apparent bias or persuasive content.

Endpoints Bias

Social Shares: 1

🔵 Liberal <—> Conservative 🔴:

🗽 Libertarian <—> Authoritarian 🚔:

🗞️ Objective <—> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <—> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <—> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <—> Pro-establishment 📺:

🙁 Negative <—> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <—> Credible ✅:

🧠 Rational <—> Irrational 🤪:

🤑 Advertising:

🔬 Scientific <—> Superstitious 🔮:

🤖 Written by AI:

💔 Low Integrity <—> High Integrity ❤️:

AI Bias: Neutral training data, no strong inclination towards any specific bias.

Article Text:
Please login or sign up to view

Close

Bearish Case: High debt levels and fierce biosimilar competition cast a shadow over revenue outlook, compounded by mixed clinical results and regulatory scrutiny.ZeroHedge Opinion 

Close

Amgen Crashes As Anti-Obesity Drug Results Disappoint; Novo & Lilly Surge On Proposed Biden Coverage Rule

Article Bias: The article discusses the fluctuating fortunes of weight-loss drugs from various companies, particularly in light of a proposed Biden administration rule, presenting a nuanced view on the pharmaceutical market dynamics while showing skepticism towards government spending on such programs and hinting at an alternative approach through healthy food, which may reflect a bias towards more conservative viewpoints on healthcare funding.

ZeroHedge Opinion Bias

Social Shares: 0

🔵 Liberal <—> Conservative 🔴:

🗽 Libertarian <—> Authoritarian 🚔:

🗞️ Objective <—> Subjective 👁️ :

🚨 Sensational:

📉 Bearish <—> Bullish 📈:

📝 Prescriptive:

🕊️ Dovish <—> Hawkish 🦁:

😨 Fearful:

📞 Begging the Question:

🗣️ Gossip:

💭 Opinion:

🗳 Political:

Oversimplification:

🏛️ Appeal to Authority:

🍼 Immature:

🔄 Circular Reasoning:

👀 Covering Responses:

😢 Victimization:

😤 Overconfident:

🗑️ Spam:

✊ Ideological:

🏴 Anti-establishment <—> Pro-establishment 📺:

🙁 Negative <—> Positive 🙂:

📏📏 Double Standard:

❌ Uncredible <—> Credible ✅:

🧠 Rational <—> Irrational 🤪:

🤑 Advertising:

👤 Individualist <—> Collectivist 👥:

🤖 Written by AI:

💔 Low Integrity <—> High Integrity ❤️:

AI Bias: Bias detail not specified, potential impartiality from diverse training data.

Article Text:
Please login or sign up to view

Close

seekingalpha.com 

Close

Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold

seekingalpha.com Bias

Social Shares: 0

This article is similar to Crescat Capital July Letter: Monetary Vs. Fiscal Dissonance

Close

Potential Outcomes:

• 40% chance of successful clinical trials boosting growth.
• 35% chance of debt pressure limiting upside.
• 25% competition from biosimilars eroding market share.HeliumHelium

Trading Oracle: Consider a short-term bullish debit spread, buying $270 calls, selling $275 calls, expiring in two months. This leverages anticipated volatility post-earnings, targeting a price rebound as volatility is expected to stabilize based on mean-reversion trends.

January 11, 2025